The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, ...

DelveInsight's Tumor-Infiltrating Lymphocyte Therapies Market Size, Target Population, Competitive Landscape & Market ...

DelveInsight's FAP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Europe's pharmaceutical companies are bracing for United States President Donald Trump's plan to slap tariffs of up to 250 ...

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

DelveInsight's CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR ...

Edmunds small luxury SUV test: 2025 Acura ADX vs 2025 BMW X1 This photo provided by Acura shows the 2025 ADX. The ADX is Acura's new small crossover SUV. It starts at $36,350, including destination.